Publications by authors named "Albert Profy"

Claim this Profile
E
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
John P Hanrahan, Ian H de Boer, George L Bakris, Phebe J Wilson, James D Wakefield, Albert T Profy

Clin J Am Soc Nephrol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells.
Guang Liu, Courtney M Shea, Juli E Jones, Gavrielle M Price, William Warren, Albert T Profy

Am J Physiol Renal Physiol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
James E Udelson, Gregory D Lewis, Sanjiv J Shah, Michael R Zile, Margaret M Redfield, Albert T Profy

JAMA· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
John P Hanrahan, Jelena P Seferovic, James D Wakefield, Phebe J Wilson, Jennifer G Chickering, Albert T Profy

Diabetologia· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).
James E Udelson, Gregory D Lewis, Sanjiv J Shah, Michael R Zile, Margaret M Redfield, Albert T Profy

Am Heart J· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats.
Ali R Banijamali, Andrew E Carvalho, James D Wakefield, Peter Germano, Timothy C Barden, Albert T Profy

Pharmacol Res Perspect· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects.
John P Hanrahan, James D Wakefield, Phebe J Wilson, Marina Mihova, Jennifer G Chickering, Albert T Profy

Clin Pharmacol Drug Dev· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.
Jenny V Tobin, Daniel P Zimmer, Courtney Shea, Peter Germano, Sylvie G Bernier, Albert T Profy

J Pharmacol Exp Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications : Bamberg, Germany. 23-25 June, 2017.
G. Todd Milne, , Peter Sandner, Kathleen A. Lincoln, Paul C. Harrison, Albert T. Profy

BMC Pharmacol Toxicol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women.
Salim S Abdool Karim, Barbra A Richardson, Gita Ramjee, Irving F Hoffman, Zvavahera M Chirenje, Albert Profy

AIDS· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.
Sheena McCormack, Gita Ramjee, Anatoli Kamali, Helen Rees, Angela M Crook, Albert Profy

Lancet· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda.
Anatoli Kamali, Helen Byomire, Catherine Muwonge, Julie Bakobaki, Clare Rutterford, Albert Profy

Sex Transm Infect· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.
Marla J Keller, Pedro M M Mesquita, N Merna Torres, Sylvia Cho, Gail Shust, Albert T Profy

PLoS One· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.
Dana Huskens, Kurt Vermeire, Albert T Profy, Dominique Schols

Antiviral Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes.
Darpun D Sachdev, Bouchra Zerhouni-Layachi, Mila Ortigoza, Albert T Profy, Michael Tuen

J Acquir Immune Defic Syndr· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides.
Carol Lackman-Smith, Clay Osterling, Katherine Luckenbaugh, Marie Mankowski, Beth Snyder, Albert Profy

Antimicrob Agents Chemother· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transfer.
Natalia Teleshova, Theresa Chang, Albert Profy, Mary E Klotman

Antimicrob Agents Chemother· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity.
Marla J Keller, Esmeralda Guzman, Ehsan Hazrati, Andrea Kasowitz, Natalia Cheshenko, Albert T Profy

AIDS· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations.
Ana C G Tuyama, Natalia Cheshenko, Maria J Carlucci, Jin-Hua Li, Cindy L Goldberg, Albert T Profy

J Infect Dis· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study.
Charles J N Lacey, Anne Wright, Jonathan N Weber, Albert T Profy

AIDS· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Documenting intermenstrual bleeding in a vaginal microbicide study: case reports and lessons learned.
Smita Joshi, Soma Dutta, Beverly Bell, Albert Profy, JoAnn Kuruc

AIDS Res Hum Retroviruses· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India.
Joshi Smita, Dutta Soma, Bell Beverly, Profy Albert, Kuruc JoAnn

AIDS Res Ther· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
Marla J Keller, Bouchra Zerhouni-Layachi, Natalia Cheshenko, Minnie John, Kathleen Hogarty, Albert T Profy

J Infect Dis· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action.
Irini A Scordi-Bello, Arevik Mosoian, Cejiang He, Yiban Chen, Yang Cheng, Albert T Profy

Antimicrob Agents Chemother· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.
Natalia Cheshenko, Marla J Keller, Veronica MasCasullo, Gary A Jarvis, Hui Cheng, Albert T Profy

Antimicrob Agents Chemother· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis